RBC Capital analyst Deane Dray raised his price target on Danaher to $107 after a "healthy" Q2 earnings beat, with "solid" organic growth across its portfolio. Dray notes that the announcement of a tax-free spin of the company's Dental unit by the second half of FY19 was a surprise but "makes sense" given the recovery of its organic growth and stabilization of channel destocking trends. The analyst keeps his Sector Perform rating on Danaher, stating that while the stock's sum-of-parts valuation is "not compelling", he is positive on the upside in the company's organic growth and capacity for more M&A.

Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.

Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.

Notable gainers among liquid option names this morning include Globe Life (GL) $71.33 +4.94, Super Micro (SMCI) $764.85 +47.83, Danaher (DHR) $250.88 +14.79, Kimberly Clark (KMB) $136.87 +7.94, and General Motors (GM) $45.38 +2.17.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here